Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 2/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.36 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.36 |
| ▸ | TGM2 | P21980 | 7/20 | 0.36 |
| ▸ | F13A1 | P00488 | 6/20 | 0.36 |
| ▸ | TGM1 | P22735 | 6/20 | 0.36 |
| ▸ | TGM3 | Q08188 | 1/20 | 0.36 |
| ▸ | DTYMK | P23919 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1344831 | 0.88 | DDB1 (0.39) | NR1H2ESR2USP2SMN1; SMN2ALDH1A1 | |
| SCHEMBL2898726 | 0.86 | MAPK1 (0.40) | NR1H2ESR2USP2SMN1; SMN2ALDH1A1 | |
| SCHEMBL1583253 | 0.83 | P2RX7 (0.46) | NR1H2ESR2USP2SMN1; SMN2ALDH1A1 | |
| SCHEMBL4005175 | 0.83 | NR1H2 (0.41) | NR1H2ESR2USP2SMN1; SMN2ALDH1A1 | |
| SCHEMBL24744821 | 0.82 | NR1H2 (0.40) | NR1H2ESR2USP2SMN1; SMN2ALDH1A1 | |
| SCHEMBL4390630 | 0.82 | NR1H2 (0.41) | NR1H2ESR2USP2SMN1; SMN2ALDH1A1 | |
| SCHEMBL1176507 | 0.82 | NR1H2 (0.40) | NR1H2ESR2USP2SMN1; SMN2ALDH1A1 | |
| SCHEMBL6969188 | 0.81 | P2RX7 (0.49) | NR1H2ESR2USP2SMN1; SMN2ALDH1A1 | |
| SCHEMBL12495387 | 0.81 | ITGB3 (0.41) | NR1H2ESR2USP2SMN1; SMN2ALDH1A1 | |
| SCHEMBL1583540 | 0.81 | CNR2 (0.40) | NR1H2ESR2USP2SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8063042-B2 | Heterocyclic compounds | HOFFMANN-LA ROCHE INC. (US) | 2011-11-22 | — | — | US | disclosed |
| EP-1534695-B1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2010-09-29 | — | — | EP | disclosed |
| EP-1534695-B1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2010-09-29 | — | — | EP | disclosed |
| EP-2220055-A2 | NOVEL HETEROCYCLYL COMPOUNDS AND THEIR USE AS CHEMOKINE ANTAGONISTS | F. Hoffmann-La Roche AG (CH) | 2010-08-25 | — | — | EP | disclosed |
| US-20090186871-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. | 2009-07-23 | — | — | US | disclosed |
| US-20090186871-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. | 2009-07-23 | — | — | US | disclosed |
| US-7560546-B2 | Tyrosine kinase inhibitors | MERCK & CO., INC. (US) | 2009-07-14 | — | — | US | disclosed |
| US-7560546-B2 | Tyrosine kinase inhibitors | MERCK & CO., INC. (US) | 2009-07-14 | — | — | US | disclosed |
| US-7560546-B2 | Tyrosine kinase inhibitors | MERCK & CO., INC. (US) | 2009-07-14 | — | — | US | disclosed |
| US-20090023713-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE, INC. | 2009-01-22 | — | — | US | disclosed |
| WO-2009010429-A2 | NOVEL HETEROCYCLYL COMPOUNDS AND THEIR USE AS CHEMOKINE ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-01-22 | — | — | WO | disclosed |
| US-20050261496-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME LLC | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261496-A1 | Tyrosine kinase inhibitors | ABL1, JAK2, ERBB2 | NR1H2 3103/4885ESR2 1803/4885USP2 2116/4885 |
| US-20090023713-A1 | HETEROCYCLIC COMPOUNDS | CCR5, CCR3, CCR2 | NR1H2 135/4885ESR2 654/4885USP2 4800/4885 |
| US-20090186871-A1 | Tyrosine kinase inhibitors | ABL1, JAK2, ERBB2 | NR1H2 3103/4885ESR2 1803/4885USP2 2116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.